Suven Life Sciences Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Suven Life Sciences achieved 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder (MDD), more than Two Months Ahead of Schedule".